halometasone + triclosan (Novartis)

Halometasone + Triclosan (often abbreviated as Hal/TCS) is a fixed-dose combination topical therapy consisting of the potent (Class III) synthetic corticosteroid halometasone and the antimicrobial agent triclosan. Halometasone exerts anti-inflammatory, antipruritic, and anti-exudative effects by binding to and activating glucocorticoid receptors, thereby modulating the expression of genes involved in the inflammatory response. Triclosan is a broad-spectrum antimicrobial that inhibits bacterial fatty acid synthesis by targeting the enoyl-acyl carrier protein reductase (FabI) enzyme. This combination is primarily indicated for the treatment of inflammatory skin conditions, such as acute and chronic eczema and various forms of dermatitis, particularly when secondary microbial infection is present or suspected. It has also been investigated for its efficacy in treating truncal vitiligo in children and adolescents. The product was originally developed by Novartis and is marketed in several regions, including China and Switzerland.

Brand names

Sicorten Plus

Other names

halometasone/triclosanhalometasone and triclosanhalomethasone + triclosan